ZFP36L2

Across TCGA pan-cancer cohorts, ZFP36L2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZFP36L2 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ZFP36L2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ZFP36L2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

CCRCC, HNSC, and LUAD are the cancer types where ZFP36L2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	0.734	1.000	.029	4	view →
HNSC	OS	Median	III,IV	1.000	0.449	.023	2	view →
LUAD	OS	Median	All	0.974	0.913	.035	2	view →
LSCC	DFS	Median	All	0.623	0.803	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ZFP36L2–CCRCC (OS)

Open the CCRCC breakdown →